Iowa City, IA9 Active Studies

Spinal Muscular Atrophy Clinical Trials in Iowa City, IA

Find 9 actively recruiting spinal muscular atrophy clinical trials in Iowa City, IA. Connect with local research sites and explore new treatment options.

9
Active Trials
8
Sponsors
1,356
Enrolling

Recruiting Spinal Muscular Atrophy Studies in Iowa City

NCT05208762Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect i...

Iowa City, IAPHASE1714 participantsSeagen, a wholly owned subsidiary of Pfizer
View Study Details
NCT04317534Recruiting

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumor...

Iowa City, IAPHASE2244 participantsGreg Durm, MD
View Study Details
NCT07006727Recruiting

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged...

Iowa City, IAPHASE1116 participantsNovartis Pharmaceuticals
View Study Details
NCT05903092Recruiting

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer

The study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks for 4 cycles. After 4 cycles, sub...

Iowa City, IAPHASE284 participantsHirva Mamdani
View Study Details
NCT07287982Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

This study aims to find the correct dose of ARGX-119 for children with SMA. The study will also look at how safe the study drug is, how well it works, how it moves through the body, and how the immune...

Iowa City, IAPHASE260 participantsargenx
View Study Details
NCT04919382Recruiting

Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metasta...

Iowa City, IAPHASE256 participantsDwight Owen
View Study Details
NCT07047144Recruiting

A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects \<2 years old with 5q autosomal recessive SMA who...

Iowa City, IAPHASE252 participantsScholar Rock, Inc.
View Study Details
NCT06107374Recruiting

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

This pilot study uses \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors. The study's main objectives are to...

Iowa City, IAPHASE220 participantsCellSight Technologies, Inc.
View Study Details
NCT06084806Recruiting

Test-retest Evaluation of [18F]F-AraG PET

This pilot study aims to evaluate the test-retest variability of \[18F\]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of \[18F\...

Iowa City, IAPHASE210 participantsCellSight Technologies, Inc.
View Study Details

About Spinal Muscular Atrophy Clinical Trials in Iowa City

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 9 spinal muscular atrophy clinical trials recruiting participants in Iowa City, IA. These studies are seeking a combined 1,356 participants. Research is being sponsored by Seagen, a wholly owned subsidiary of Pfizer, Greg Durm, MD, Novartis Pharmaceuticals and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in Iowa City — FAQ

Are there spinal muscular atrophy clinical trials in Iowa City?

Yes, there are 9 spinal muscular atrophy clinical trials currently recruiting in Iowa City, IA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Iowa City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Iowa City research site will contact you about next steps.

Are clinical trials in Iowa City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Iowa City studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 9 active trials in Iowa City are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated July 20, 2026 from ClinicalTrials.gov